HALOPERIDOL INJECTION 5 MG
HALOPERIDOL : 5 MG · DIN 02366010 · OMEGA LABORATORIES LIMITED
Health Canada status: MARKETED
What is HALOPERIDOL INJECTION?
HALOPERIDOL INJECTION 5 MG contains HALOPERIDOL : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 02366010, held by OMEGA LABORATORIES LIMITED, supplied as SOLUTION for INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 20-Aug-2026. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is HALOPERIDOL INJECTION used for?
Rapid control of acute schizophrenia and manic states; management of aggressive/agitated behaviour in chronic brain syndrome or mental retardation; Gilles de la Tourette’s syndrome.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02366010 |
|---|---|
| Brand name | HALOPERIDOL INJECTION |
| Generic / active ingredient | HALOPERIDOL : 5 MG |
| Manufacturer | OMEGA LABORATORIES LIMITED |
| Strength | 5 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAMUSCULAR |
| Schedule | Prescription |
| ATC code | N05AD01 HALOPERIDOL |
| AHFS class | 28:16.08.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 20-Aug-2026 |
| Original market date | 2011-09-19 00:00:00 |
How is it administered?
For intramuscular injection only. Rapid control of acute states: 2 to 5 mg IM. Subsequent doses may be given every 4 to 8 hours. NOT FOR intravenous use.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly stated in provided text (standard practice is 15-30°C, but not in snippet).
How is it supplied?
5 mg / mL, 1 mL vial.
Contraindications
Intravenous use; comatose states; CNS depression (alcohol/drugs); severe depressive states; spastic diseases; Parkinson’s syndrome; sensitivity to haloperidol; children.
Warnings and precautions
NOT FOR IV USE. Risk of sudden death, QT prolongation, and Torsade de Pointes. Neuroleptic Malignant Syndrome, Tardive Dyskinesia, and Venous Thromboembolism reported.
Is HALOPERIDOL in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by OMEGA LABORATORIES LIMITED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N05AD01 HALOPERIDOL. 9 of 51 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| HALOPERIDOL INJ 5MG/ML USP | 5 MG | LIQUID | SANDOZ CANADA INCORPORATED | MARKETED | DIN 00808652 |
| HALOPERIDOL INJECTION, USP | 5 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02406411 |
| HALOPERIDOL LA | 100 MG | LIQUID | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02130300 |
| TEVA-HALOPERIDOL | 0.5 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 00363685 |
| TEVA-HALOPERIDOL | 1 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 00363677 |
| TEVA-HALOPERIDOL | 10 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 00713449 |
| TEVA-HALOPERIDOL | 2 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 00363669 |
| TEVA-HALOPERIDOL | 5 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 00363650 |
| APO HALOPERIDOL TAB 0.5MG | .5 MG | TABLET | APOTEX INC | DORMANT | DIN 00396796 |
| APO HALOPERIDOL TAB 1MG | 1 MG | TABLET | APOTEX INC | DORMANT | DIN 00396818 |
Who else supplies HALOPERIDOL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. HALOPERIDOL appears in 2739 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.